SwissBioGrid
 
 Proof of Concept study
 GRID Middleware
 Bio-data Project
 Astigmatism Contact Lenses
 Bill Cosby Tickets
 ACDC Tickets
 Home
 


Proof of Concept Pilot project:
High throughput Docking for Dengue

Scope and objectives
Dengue is primarily a disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Infection with dengue viruses produces a spectrum of clinical illness ranging from a non-specific viral syndrome to severe or fatal hemorrhagic disease. While a major objective of pharmaceutical research is to discover novel medicines that improve the quality of life of the human population, diseases which affect mainly the developing countries are of limited commercial potential under the conventional business model of large pharma companies. As a consequence, these diseases are not the primary focus of the industry, and alternative efforts – with support by the industry which holds the Drug Discovery know how – are needed to drive the discovery of new medicines for these diseases. In this context, we propose a project which is aimed at the computational screening of small compounds – available in public libraries – to identify very early drug candidates, which could interact with the molecular targets of the dengue viruses.

Value
This project would allow us to demonstrate the feasibility and viability of the Compute GRID aspect of the Swiss Bio Grid, using an approach which has already been validated in industry (High Throughput Docking on a general purpose Compute Grid). The value of the project can be perceived in several dimensions:

  • Establish a computational ligand-finding platform (server) which can be used for many other molecular targets, with an emphasis on orphan diseases. The platform would also provide centralized access to structural data, both for proteins and small molecular entities.
  • The most promising compounds identified by computational screening will be transferred to interested parties with the capability to further analyze their value in a Drug Discovery program aimed at treating Dengue. Such parties may include institutions like the Novartis Institute for Tropical Diseases in Singapore.
  • Provide students with the opportunity to be confronted with Drug Discovery problems, which will benefit the industry by training future highly skilled drug discovery scientists.
  • Position Switzerland on the map of nations searching for solutions for orphan diseases, an activity which is compatible with the aspirations of its population. This would also represent a sensible way to support developing countries with future government investment.
     
Feasibility
The High Throughput Docking approach has been developed in the public domain and a series of computational methods and software tools are available. These have been implemented and validated by the pharmaceutical industry, where considerable know-how about their respective value has been collected. The transfer of this know-how, including the running of a robust computational system, will be a key aspect of this pilot project. As these lines are written, all key components of this project are being established at one of the member sites, demonstrating its high probability of success.


Outlook
This pilot project has the potential to provide two sustained benefits:
  • The basic functionality for a Compute Grid in Switzerland, which can then be applied to other computationally intensive problems in the life sciences.
  • A public computational ligand-finding platform, which can be applied to many more targets than those of the Dengue Virus.

Contacts Coupon Codes
Get your coupon codes to save money on your purchase of contact lenses.

 

 
 
 
 

Active site of dengue methyltransferase protein with bound ligand (PDB:1R6A)
Source: M. Podvinec, Biozentrum
Home © All Rights Reserved